KDNY
Chinook Therapeutics, Inc.
Set alert
52-week range unavailable
- Open
- 40.31
- Prev close
- 40.39
- Mkt cap
- 2.63B
- Vol
- 3.28M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 40.30
- High
- 40.51
- Forward P/E
- -11.37
- Beta
- 0.68
- Short ratio
- 1.24
- Inst. own
- 96.29%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2023
- 50-d avg
- 29.15
- 200-d avg
- 24.27
- 1y target
- 39.30
Key statistics
- Market cap
- 2.63B
- Enterprise value
- 2.30B
- Trailing P/E
- 0.00
- Forward P/E
- -11.37
- PEG ratio
- -1.36
- Price / sales
- 500.03
- Price / book
- 6.35
- EPS (TTM)
- -3.23
- Beta
- 0.68
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 5.26M
- Revenue growth
- -32.20%
- Free cash flow
- -84.44M
- Total cash
- 350.38M
- Total debt
- 38.26M
- Return on equity
- -51.56%
- Shares outstanding
- 67.05M
- Short % of float
- 5.44%
- 50-day average
- 29.15
- 200-day average
- 24.27
Analyst view
Consensus: buy
- Target (low)
- 30.00
- Target (mean)
- 39.30
- Target (high)
- 47.00
Next earnings
Aug 7, 2023
Expected Aug 7, 2023. Consensus EPS estimate -0.81.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 7, 2023 | Jun 1, 2023 | -0.81 | — | — | — |
| May 9, 2023 | Mar 1, 2023 | -0.80 | — | — | — |
| Feb 27, 2023 | Dec 1, 2022 | -0.79 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -0.62 | — | — | — |
| Aug 8, 2022 | Jun 1, 2022 | -0.62 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -0.68 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 21, 2023 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Jun 14, 2023 | Evercore ISI Group | down | Outperform | In-Line |
| Jun 13, 2023 | Stifel | down | Buy | Hold |
| Jun 13, 2023 | SVB Leerink | down | Outperform | Market Perform |
| Jun 13, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 12, 2023 | Cantor Fitzgerald | down | Overweight | Neutral |
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- chinooktx.com
News
Your note
Sign in to keep a note on KDNY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | Conversion of Exercise of derivative security | May 25, 2023 | 3,300 |
| BJERKHOLT ERIC H | Chief Financial Officer | Sale | Feb 9, 2023 | 38,867 |
| DAVIS JEREL C | Director | Conversion of Exercise of derivative security | May 25, 2023 | 733,770 |
| DOBMEIER ERIC L | Chief Executive Officer | Sale | Apr 23, 2023 | 301,138 |
| GREENMAN WILLIAM MARINER | Director | Sale | May 29, 2023 | 23,643 |
| GRIFFIN MICHELLE RENEE | Director | Conversion of Exercise of derivative security | May 25, 2023 | 3,300 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 7.72% | 5,161,888 | 202.45M | Mar 30, 2023 |
| Frazier Life Sciences Management, L.P. | 6.50% | 4,345,559 | 170.43M | Mar 30, 2023 |
| Blackrock Inc. | 5.89% | 3,942,539 | 154.63M | Mar 30, 2023 |
| Deep Track Capital, LP | 4.49% | 3,000,000 | 117.66M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 4.26% | 2,847,835 | 111.69M | Mar 30, 2023 |
| State Street Corporation | 4.02% | 2,688,048 | 105.43M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.60% | 1,709,505 | 67.05M | Dec 30, 2022 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.24% | 1,476,666 | 57.91M | Feb 27, 2023 |
| iShares Russell 2000 ETF | 1.69% | 1,112,841 | 43.65M | Feb 27, 2023 |
| Vanguard Extended Market Index Fund | 0.91% | 602,215 | 23.62M | Dec 30, 2022 |
| iShares Russell 2000 Value ETF | 0.77% | 509,205 | 19.97M | Feb 27, 2023 |
| Federated Hermes Kaufmann Fund | 0.68% | 450,000 | 17.65M | Jan 30, 2023 |